Evidence map›Paper›PMID 37794808›Full record

ArticleHaematologica2024

A patient with minimal myeloma treatment who survived for 20 years.

Alenka Djarmila Behsen, Esten Nymoen Vandsemb, Tobias Schmidt Slørdahl, Henrik Hjorth-Hansen, Petter Quist-Paulsen, Kristine Misund, Anne-Marit Sponaas, Anders Waage

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alenka Djarmila BehsenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim. alenka.d.behsen@ntnu.no.
Esten Nymoen VandsembDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
Tobias Schmidt SlørdahlDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Hematology, St. Olavs Hospital, Trondheim.
Henrik Hjorth-HansenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Hematology, St. Olavs Hospital, Trondheim.
Petter Quist-PaulsenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Hematology, St. Olavs Hospital, Trondheim.
Kristine MisundDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Medical Genetics, St. Olavs Hospital, Trondheim.
Anne-Marit SponaasDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
Anders WaageDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Biobank1, St. Olavs Hospital, Trondheim.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaHumans

Identifiers

PMID37794808
PMCPMC10988195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.